Safety of vaginal oestrogens for genitourinary symptoms in women with breast cancer

被引：0

作者：

Kiely, Belinda E. ^{[1
,2
,3
]}

Liang, Rhea ^{[4
,5
]}

Jang, Christina ^{[6
,7
]}

Magraith, Karen ^{[8
,9
,10
]}

机构：

[1] Campbelltown Hosp, Dept Med Oncol, Sydney, NSW, Australia

[2] Concord Hosp, Dept Med Oncol, Sydney, NSW, Australia

[3] Univ Sydney, NHMRC, Clin Trials Ctr, Sydney, NSW, Australia

[4] Gold Coast Hosp, Gold Coast, Qld, Australia

[5] Bond Univ, Gold Coast, Qld, Australia

[6] Royal Brisbane & Womens Hosp, Dept Endocrinol & Diabet, Brisbane, Qld, Australia

[7] Univ Queensland, Fac Med, Brisbane, Qld, Australia

[8] Cascade Rd Gen Practice, Hobart, Tas, Australia

[9] Univ Tasmania, Sch Med, Hobart, Tas, Australia

[10] Australasian Menopause Soc, Healesville, Vic, Spain

来源：

AUSTRALIAN JOURNAL OF GENERAL PRACTICE | 2024年 / 53卷 / 05期

关键词：

AROMATASE INHIBITORS; UROGENITAL ATROPHY; THERAPY; MANAGEMENT; METAANALYSIS; MENOPAUSE; SURVIVORS;

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Background Oestrogen deprivation is the mainstay of treatment for women with hormone receptor -positive breast cancer, but unfortunately it causes multiple side effects that can significantly impair quality of life. Genitourinary symptoms are very common and although these symptoms can be effectively managed with vaginal oestrogens, concerns about their safety in women with breast cancer limits their use. Objective The aim of this review is to provide a summary of the data on the safety of vaginal oestrogens in women with breast cancer to help general practitioners advise their patients in this situation. Discussion Although there are no large randomised prospective studies to assess safety, the current evidence suggests reassurance can be provided to the majority of women with a history of breast cancer considering vaginal oestrogens. Consultation with the oncology team is advised for women taking aromatase inhibitors, where the safety of vaginal oestrogens is less certain.

引用

页码：305 / 310

页数：6

共 27 条

[1] Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview [J].

Al-Baghdadi, O. ;

Ewies, A. A. A. .

CLIMACTERIC, 2009, 12 (02) :91-105

[2] Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance) [J].

Barton, Debra L. ;

Sloan, Jeff A. ;

Shuster, Lynne T. ;

Gill, Paula ;

Griffin, Patricia ;

Flynn, Kathleen ;

Terstriep, Shelby A. ;

Rana, Fauzia N. ;

Dockter, Travis ;

Atherton, Pamela J. ;

Tsai, Michaela ;

Sturtz, Keren ;

Lafky, Jacqueline M. ;

Riepl, Mike ;

Thielen, Jacqueline ;

Loprinzi, Charles L. .

SUPPORTIVE CARE IN CANCER, 2018, 26 (02) :643-650

[3] Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer [J].

Baumgart, Juliane ;

Nilsson, Kerstin ;

Evers, Anneli Stavreus ;

Kallak, Theodora Kunovac ;

Poromaa, Inger Sundstrom .

MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2013, 20 (02) :162-168

[4]

Cancer Australia, 2020, GUID MAN EARL BREAST

[5] Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: Second report of the hormones and urogenital therapy committee [J].

Cardozo, L ;

Bachmann, G ;

McClish, D ;

Fonda, D ;

Birgerson, L .

OBSTETRICS AND GYNECOLOGY, 1998, 92 (04) :722-727

[6] First uterine pass effect is observed when estradiol is placed in the upper but not lower third of the vagina [J].

Cicinelli, E ;

de Ziegler, D ;

Morgese, S ;

Bulletti, C ;

Luisi, D ;

Schonauer, LM .

FERTILITY AND STERILITY, 2004, 81 (05) :1414-1416

[7] Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study [J].

Cold, Soren ;

Cold, Frederik ;

Jensen, Maj-Britt ;

Cronin-Fenton, Deirdre ;

Christiansen, Peer ;

Ejlertsen, Bent .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2022, 114 (10) :1347-1354

[8] Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials [J].

Dowsett, M. ;

Forbes, J. F. ;

Bradley, R. ;

Ingle, J. ;

Aihara, T. ;

Bliss, J. ;

Boccardo, F. ;

Coates, A. ;

Coombes, R. C. ;

Cuzick, J. ;

Dubsky, P. ;

Gnant, M. ;

Kaufmann, M. ;

Kilburn, L. ;

Perrone, F. ;

Rea, D. ;

Thuerlimann, B. ;

van de Velde, C. ;

Pan, H. ;

Peto, R. ;

Davies, C. ;

Gray, R. ;

Baum, M. ;

Buzdar, A. ;

Sestak, I. ;

Markopoulos, C. ;

Fesl, C. ;

Jakesz, R. ;

Colleoni, M. ;

Gelber, R. ;

Regan, M. ;

von Minckwitz, G. ;

Snowdon, C. ;

Goss, P. ;

Pritchard, K. ;

Anderson, S. ;

Costantino, J. ;

Mamounas, E. ;

Ohashi, Y. ;

Watanabe, T. ;

Bastiaannet, E. .

LANCET, 2015, 386 (10001) :1341-1352

[9] The 2022 hormone therapy position statement of The North American Menopause Society [J].

Faubion, Stephanie S. ;

Crandall, Carolyn J. ;

Davis, Lori ;

El Khoudary, Samar R. ;

Hodis, Howard N. ;

Lobo, Roger A. ;

Maki, Pauline M. ;

Manson, JoAnn E. ;

Pinkerton, JoAnn V. ;

Santoro, Nanette F. ;

Shifren, Jan L. ;

Shufelt, Chrisandra L. ;

Thurston, Rebecca C. ;

Wolfman, Wendy .

MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2022, 29 (07) :767-794

[10] Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health [J].

Faubion, Stephanie S. ;

Larkin, Lisa C. ;

Stuenkel, Cynthia A. ;

Bachmann, Gloria A. ;

Chism, Lisa A. ;

Kagan, Risa ;

Kaunitz, Andrew M. ;

Krychman, Michael L. ;

Parish, Sharon J. ;

Partridge, Ann H. ;

Pinkerton, JoAnn V. ;

Rowen, Tami S. ;

Shapiro, Marla ;

Simon, James A. ;

Goldfarb, Shari B. ;

Kingsberg, Sheryl A. .

MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2018, 25 (06) :596-608

← 1 2 3 →